Pure Global: US LDTs, the FDA's Regulatory Wake-Up Call

Failed to add items

Sorry, we are unable to add the item because your shopping basket is already at capacity.

Add to cart failed.

Please try again later

Add to wishlist failed.

Please try again later

Remove from wishlist failed.

Please try again later

Follow podcast failed

Unfollow podcast failed

Pure Global: US LDTs, the FDA's Regulatory Wake-Up Call

Listen for free

View show details

About this listen

The U.S. FDA has just upended the diagnostics world. After decades of operating in a regulatory gray area, laboratory-developed tests (LDTs) will now be regulated as medical devices. This episode of MedTech Global Insights dives deep into what this massive policy shift means for labs, patients, and the entire MedTech industry. We explore the end of the FDA's "enforcement discretion" policy and the beginning of a new era of compliance. We unpack the immense operational and financial challenges facing academic medical centers and specialized labs, who must now navigate the same stringent requirements as major IVD manufacturers. A Real-World Dilemma: Imagine a university lab that developed a groundbreaking genomic test for a rare pediatric cancer. Now, they are considered a medical device manufacturer by the FDA, facing a multi-million dollar compliance burden without the staff or budget. Will their vital test disappear, leaving patients with no options? This is the reality many labs now face. Key Takeaways From This Episode: - Why did the FDA decide to regulate LDTs as devices after decades? - What is the four-year transition timeline, and what are the key compliance deadlines? - How will pre-market review requirements impact innovation in personalized medicine? - What are the strategic options for labs: build, partner, or discontinue tests? - Will this new rule create more opportunities for large IVD companies? - How can labs with limited resources begin building a compliant Quality Management System? - What happens to niche tests for rare diseases that may not be commercially viable under this new rule? For more information, contact us at info@pureglobal.com or visit https://pureglobal.com/. You can also explore our FREE AI tools and medical device database at https://pureglobal.ai/.

No reviews yet